APBN New Site

APBN Developing Site

Research Partnership Between BAYER and RIKEN Innovation to Boost Drug Discovery Opportunities

Announced in October 2019, the collaboration aims to explore novel drug discovery opportunities and identify joint research projects.

RIKEN Innovation established by Japan’s largest national research organization for basic and applied science and a world leader in a diverse array of scientific disciplines is responsible for business relevant to industry-academia collaboration.

Drawing on their excellence in basic research and Bayer’s expertise in global drug discovery, both partners will jointly explore potential drug targets, utilize basic drug discovery technologies as well as assess disease mechanisms.

“The key to discovering and developing new therapeutic options for patients around the world is collaboration between industry and competent partners in academia. We are extremely honoured to be able to pursue innovation together with RIKEN, one of the world’s top national research institutes. We firmly believe that this partnership will help to advance science to the benefit of patients suffering from severe disease conditions,” said Dr Joerg Moeller, Member of the Executive Committee of Bayer AG’s Pharmaceuticals Divisions and Head of Research and Development.

With over 100 years of history, RIKEN is Japan’s largest national research organization with more than 3,500 employees across 10 research sites including Kobe, Osaka, Tokyo, Harima, Yokohama and Wako. RIKEN Innovation’s efforts span a diverse range of scientific disciplines including cell and developmental biology, neuroscience, immunology, and AI technology, and various interdisciplinary fields, producing about 2,500 publications annually.

“This partnership will enable collaboration between scientists at RIKEN and at Bayer, a global company that has contributed to healthcare innovation in Japan for more than 100 years,” said Hiroshi Matsumoto, President of RIKEN. “The newly established RIKEN Innovation will support this partnership’s advancement by seamlessly connecting the scientific expertise and resources of both Bayer and RIKEN.”

“Our company was founded as an external entity to support RIKEN in promoting and facilitating industry-academia collaboration,” said Yoshihiro Aburatani, President of RIKEN Innovation. “Our purpose is to expedite the process of putting RIKEN’s research achievements to work for society, and to enable collaboration with industry partners. Our partnership with Bayer is a meaningful first step in growing our industry-academia scientific collaboration. We will work closely with RIKEN and do our best in advancing this partnership.” [APBN]